APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial
JCO Precision Oncology · 2026-08 · 10 (8)
DOI: 10.1200/po-25-01012 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Xiaolei Shi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Prostatic Neoplasms, Steroid Isomerases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE A six-gene panel involved in androgen production, uptake, and conversion (APUC-6: HSD3B1 , HSD3B2 , CYP3A43 , CYP11A1 , CYP11B1 , CYP17A1 ) may define distinct clinical outcomes in metastatic prostate cancer. This study evaluated the prognostic and predictive value of APUC-6 expression in metastatic castration-sensitive prostate cancer (mCSPC). METHODS Transcriptomic data from 160 patients in the phase III Eastern Cooperative Oncology Group-ACRIN E3805 CHAARTED trial were analyzed. Patients were stratified into four subgroups based on APUC-6 and androgen receptor ( AR ) gene expression. Clinical outcomes including time to clinical progression (ttCP), time to castration resistance (ttCR), and overall survival (OS) were assessed within the androgen deprivation therapy (ADT) and docetaxel plus ADT (D-ADT) arms. Interaction testing evaluated the predictive value of APUC-6/ AR status. Subgroup analyses were also performed by Decipher genomic risk. RESULTS Patients with APUC-6-high/AR-low expression showed significantly improved ttCP (hazard ratio [HR], 0.43 [95% CI, 0.22 to 0.82]; P = .0092), ttCR (HR, 0.56 [95% CI, 0.32 to 1]; P = .049), and OS (HR, 0.31 [95% CI, 0.16 to 0.61]; P = .0003), but did not appear to benefit from the addition of docetaxel. Conversely, APUC-6–low/ AR -low patients demonstrated significantly improved outcomes with D-ADT (ttCP: HR, 0.37 [95% CI, 0.21 to 0.65]; P = .00036; ttCR: HR, 0.38 [95% CI, 0.23 to 0.64]; P = .00017; OS: HR, 0.39 [95% CI, 0.21 to 0.72]; P = .0019). Statistical interaction analysis supported that patients with APUC-6–low/ AR -low expression were more likely to benefit from docetaxel (HR, 0.36 [95% CI, 0.19 to 0.66]; P = .001). For patients with a high Decipher genomic classifier score, those in the APUC-6–low subgroup had improved survival with D-ADT, whereas those in the APUC-6–high subgroup did not gain any additional benefit from docetaxel. CONCLUSION APUC-6 expression and AR gene expression define clinically relevant subgroups in mCSPC and may enhance precision medicine treatment approaches in combination with other transcriptomic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD.
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
- Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY.
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
- Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID-Profile: Xiaolei Shi, Amol C Shetty, Jarey Wang, Yang Song, Philip A Sutera, Matthew P Deek, Krishnan R Patel, Ravi A Madan, Chad Tang, Arif Hussain, Christopher Sweeney, Kristine P Lacuna, Emmanuel S Antonarakis, Phuoc T Tran, Justin Hwang
Förderung
- NCI NIH HHS
Zitieren
APA
Shi, X., Shetty, A. C., Wang, J., Song, Y., Sutera, P. A., Deek, M. P., Patel, K. R., Madan, R. A., Tang, C., Proudfoot, J., Davicioni, E., Hussain, A., Nguyen, P., Sweeney, C., Boytim, E., Lacuna, K. P., Ryan, C. J., Antonarakis, E. S., Tran, P. T., & Hwang, J. (2026). APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-25-01012
Vancouver
Shi X, Shetty AC, Wang J, Song Y, Sutera PA, Deek MP, et al. APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-25-01012
BibTeX
@article{Shi2026,
author = {Shi, Xiaolei and Shetty, Amol C and Wang, Jarey and Song, Yang and Sutera, Philip A and Deek, Matthew P and Patel, Krishnan R and Madan, Ravi A and Tang, Chad and Proudfoot, James and Davicioni, Elai and Hussain, Arif and Nguyen, Paul and Sweeney, Christopher and Boytim, Ella and Lacuna, Kristine P and Ryan, Charles J and Antonarakis, Emmanuel S and Tran, Phuoc T and Hwang, Justin},
title = {APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {8},
doi = {10.1200/po-25-01012}
}
EUVIMED